Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Jul 20, 2010

Premium

Illumina has named Melina Cimler to be vice president of quality and regulatory affairs. She will lead the company's quality and regulatory organizations to support its development, manufacturing, and distribution activities. Cimler formerly worked in similar positions at Beckman Coulter, Abbott Molecular, and Gen-Probe. Prior to joining Illumina, Cimler was president of PandiaDx Consulting. She holds a PhD in pharmacology from the University of Washington.

As an incentive to join the company, Illumina has granted Cimler an option to purchase 120,000 shares of its common stock. The option's terms are an exercise price equal to the closing fair market value of Illumina's common stock on the grant date of July 12, 2010; a 10-year term, and vesting over four years with 25 percent of the option vesting one year from the grant date and 1/48th of the option vesting monthly thereafter.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.